Has Michael Abboud, MD received payments from drug or device companies?

Yes. Drug and device makers reported $734 in general payments to Michael Abboud, MD across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Abboud, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Abboud, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Abboud, MD

Surgery · Reading, PANPI 1568632263

Payments from drug & device makers

$734in general payments, 2019–2025

Across 29 payments — averaging $25.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$141
AstraZeneca$125
GSK$112
Integra Lifesciences Corporation$80
Davol Inc.$44
Baxter Healthcare$36
plus $196 from 9 others

What the payments were for

Consulting fees$223%
Food & beverage$69294%
Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	5	$141
AstraZeneca	1	$125
GSK	5	$112
Integra Lifesciences Corporation	4	$80
Davol Inc.	1	$44
Baxter Healthcare	2	$36
KCI USA, Inc.	2	$32
Innocoll Pharmaceuticals Limited	1	$29
Focal Therapeutics, Inc.	2	$28
Z-medica, LLC	1	$22
Intuitive Surgical	1	$21
CSL Behring	1	$20
Solventum Corporation	1	$16
TELA Bio, Inc.	1	$15
Pfizer	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ANDEXXA$125

How this compares

$734 in reported general payments places this provider in the 40th percentile of 1,424 surgery providers in Pennsylvania.

See all surgery providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$108,267

Medicare patients

203

Services billed

512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	85	$234
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	13	$60

Paid to pharmacies, not to this prescriber.